Pfiz­er and CD­MOs ramp up Paxlovid man­u­fac­tur­ing with Kala­ma­zoo plant ex­pan­sion lead­ing the way

As the Covid-19 pan­dem­ic con­tin­ues to evolve, phar­ma com­pa­nies and man­u­fac­tur­ers are ex­plor­ing how to step up pro­duc­tion on an­tivi­rals.

Pfiz­er is plan­ning to ex­pand its Kala­ma­zoo-area fa­cil­i­ty to in­crease man­u­fac­tur­ing ca­pa­bil­i­ties for the oral Covid-19 an­tivi­ral Paxlovid, ac­cord­ing to a re­port from Michi­gan-based news site MLive. The ex­pan­sion of the fa­cil­i­ty, which serves as Pfiz­er’s largest man­u­fac­tur­ing lo­ca­tion, is ex­pect­ed to cre­ate hun­dreds of “high-skilled” STEM jobs, MLive re­port­ed. No de­tails about the project’s cost and time­line have been re­leased, but ac­cord­ing to MLive, Pfiz­er will an­nounce the de­tails of the ex­pan­sion at some point in ear­ly June.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER